# JOANNA RUTH BELL FOUNDATION

## Details

- **Country:** England &amp; Wales
- **Charity number:** 1207023
- **Status:** Registered
- **Legal form:** Charitable company
- **Company number:** [15257599](https://find-and-update.company-information.service.gov.uk/company/15257599)
- **Registered:** Feb. 14, 2024
- **Register:** https://register-of-charities.charitycommission.gov.uk/en/charity-search/?p_p_id=uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;_uk_gov_ccew_onereg_charitydetails_web_portlet_CharityDetailsPortlet_regId=1207023


## Contact

- **Address:** Mardale, Manor Road, Wantage
- **Postcode:** OX12 8DW
- **Phone:** 07549 764943
- **Email:** info@jrbfNF1.org
- **Website:** https://joannaruthbellfoundation.org/



## Activities

**Objects:** THE OBJECTS OF THE CIO ARE, FOR THE PUBLIC BENEFIT, THE RELIEF OF SICKNESS AND THE PRESERVATION OF HEALTH AMONG PEOPLE SUFFERING FROM NEUROFIBROMATOSIS (NF) AND NF-RELATED DISEASES THROUGH:4.1 THE PROVISION OF FUNDING TO ADVANCE MEDICAL RESEARCH INTO, AND THERAPEUTICS AND TREATMENTS FOR, NF AND NF-RELATED DISEASES (IN PARTICULAR NEUROFIBROMATOSIS TYPE 1); AND4.2 THE PROVISION OF ASSISTANCE AND SUPPORT FOR SUCH CHARITABLE PROJECTS, SERVICES, AND ACTIVITIES WHICH PROVIDE RELIEF TO PEOPLE SUFFERING FROM NF AND NF-RELATED DISEASES.

**Activities:** JRBF focuses on helping people with Neurofibromatosis (NF) with a specific focus on Neurofibromatosis type 1 (NF1) in two main ways: 1) Advancing medical research and 2) providing support and assistance for projects and activities that directly aid and provide relief to individuals.




## Classification

- **How:** Makes Grants To Organisations, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives



## Geography

- United States
- Throughout England And Wales





## Trustees

| Name | Role | Appointed |
|---|---|---|
| **Dr Joel Richard Bell** | Chair | Nov. 3, 2023 |
| Dr Leslie Anne Duncan |  | Sept. 22, 2024 |
| Dr William Joel Waldock |  | Sept. 6, 2025 |
| Ethan Gottlieb Kuhn |  | Nov. 3, 2023 |




